You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Lowering the burden of medical translation by enabling international healthcare professionals as human editors of machine translations

    SBC: Transcendent International, LLC            Topic: NIMHD

    PROJECT SUMMARY Language access solutions in healthcare have focused almost exclusively on the provision of verbal medical interpretation, despite federal and state laws that mandate translation of written information for patients with limited English proficiency (LEP). In recent years, machine translation (MT) has made significant strides, but when it comes to mission-critical technical materials ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Promoting Linguistic and Cultural Identity through Bilingual Children's Stories to Address Nutrition and Health in Indigenous Communities

    SBC: Transcendent International, LLC            Topic: 102

    PROJECT SUMMARY Children from American Indian and Alaska Native (AI/AN) backgrounds in the United States experience disproportionate health disparities, including high rates of diabetes, obesity, and dental caries, when compared to all other groups. The historial nutrition transition from a traditional diet to a more contemporary diet that is high in saturated fats, cholesterol, and sodium present ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer

    SBC: Sapience Therapeutics Inc.            Topic: NCI

    ABSTRACT Dysregulated overexpression and hyperactivation of Wnt/-catenin signaling is found in rt20% of all cancers and in 50% of breast cancer, particularly triple negative breast cancer (TNBC). Yet despite extensive efforts to inhibit Wnt/-catenin signaling, no drugs that target the Wnt pathway have been approved, mainly due to the inability of inhibitors drugs to separate oncogenic from h ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. VIPCare: Virtual Predictive Care workflow with integrated surveillance for optimal care protocol selection and management in at-risk prostate cancer patients

    SBC: VIZLITICS INC            Topic: 101

    Abstract Prostate cancer is the leading cancer diagnosis in men (not including skin cancer) and has high survival rates (98% at 5 years), resulting in an estimated 3.2M US men currently living with prostate cancer. However, data shows follow up among prostate cancer patients remains a significant challenge. A recent study at Dana- Farber/Brigham and Women’s Cancer Center (DF/BCC) demonstrated it ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Therapy and Prophylaxis for Genital Tract Infection

    SBC: THERAPYX, INC.            Topic: NIAID

    ABSTRACT GneX12 is a patented therapeutic vaccine in development specifically for women with Neisseria gonorrhoeae (gonorrhea) infection. It is a novel formulation of recombinant human interleukin-12 (IL-12) encapsulated in biodegradable sustained release micro-particles. It is meant to be given in conjunction with standard of care antibiotics to turn infections into live vaccines that generate pr ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Targeting inflammation and oxidative stress to treat acute lung injury with CNP-miR146a

    SBC: CERIA THERAPEUTICS INC            Topic: NHLBI

    SUMMARYAcute respiratory distress syndrome (ARDS) accounts for 10% of ICU admissions worldwide, with a mortality as high as 46%. ARDS incidence has risen dramatically during the COVID-19 pandemic. Despite improvements in critical care and early detection of lung injury, the management of ARDS remains largely supportive. Although mechanical ventilation may provide the necessary life support, impair ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Leveraging Label-Free Digital Imaging to Enable Rapid On-Site Evaluation (ROSE) During Thyroid Biopsy Procedures

    SBC: PATHWARE INC.            Topic: 102

    Project Summary/Abstract Pathware is developing Bioptic™, an imaging platform to analyze biopsy samples at the point-of-care. The system will rapidly digitize unstained biopsy samples and utilize computer-aided detection/diagnostics to enable quick and efficient evaluations by pathologists. Typical barriers to point-of-care diagnostics are overcome by combining novel computational microscopy wit ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Modeling the Responsiveness of Sensitive Populations to Genotoxic Agents Using DNA Repair Inhibitors

    SBC: Litron Laboratories Ltd            Topic: R

    Project Summary It is well recognized that conventional toxicology assays exhibit a crucial deficiency. Specifically, their use of limited numbers of cell lines and rodent strains does not provide information about toxic responses that may occur in sensitive human populations. Although studying very large numbers of cell lines and laboratory rodent models could theoretically address this issue, it ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. An Advanced Dermal Regeneration Scaffold for Reconstructive Surgery

    SBC: FESARIUSTHERAPEUTICS INC            Topic: NIAMS

    PROJECT SUMMARY/ABSTRACT Due to the inability of the dermis to regenerate on its own, large full thickness skin loss cannot be restored naturally. The current gold standard treatment involves autologous tissue transfer in which the patient serves as their own donor, which may be challenging due to limited availability of full thickness skin donor sites and donor- site morbidity. Dermal Replacement ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. CD3 bispecific for the treatment of ROR2-positive NSCLC

    SBC: TRAVERSE BIOTECH II INC            Topic: 102

    Project Summary We are developing a novel CD3-bispecific antibody product, TB-Bs1, for the treatment of lung cancer. Lung cancer is the leading cause of cancer deaths in both men and women in the U.S. each year, with non-small cell lung cancer (NSCLC) making up the majority of cases. NSCLC also has one of the lowest survival rates, with 5- year survival for new diagnoses at only 18%. Treatment opt ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government